Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model.

Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D'Angelo RC, Korkaya S, Baker TL, Esen ES, Prat A, Liu S, Kleer CG, Thomas DG, Wicha MS, Korkaya H.

Oncogene. 2015 Feb 5;34(6):671-80. doi: 10.1038/onc.2014.4. Epub 2014 Feb 17.

2.

MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.

Paulson AK, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, Pettinga JE, Melnik MK, Vande Woude GF, Graveel CR.

Mol Cancer Res. 2013 Sep;11(9):1112-21. doi: 10.1158/1541-7786.MCR-13-0042. Epub 2013 Jul 3.

3.

Programmed cell-to-cell variability in Ras activity triggers emergent behaviors during mammary epithelial morphogenesis.

Liu JS, Farlow JT, Paulson AK, Labarge MA, Gartner ZJ.

Cell Rep. 2012 Nov 29;2(5):1461-70. doi: 10.1016/j.celrep.2012.08.037. Epub 2012 Oct 4.

4.

Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.

Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK, Chung S, Luther T, Paholak HJ, Liu S, Hassan KA, Zen Q, Clouthier SG, Wicha MS.

Mol Cell. 2012 Aug 24;47(4):570-84. doi: 10.1016/j.molcel.2012.06.014. Epub 2012 Jul 19.

Supplemental Content

Loading ...
Support Center